Promethazine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
Neil.m.young (talk | contribs) (Text replacement - "1 mg" to "1mg") |
||
| Line 22: | Line 22: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Only Approved for >2 years=== | ===Only Approved for >2 years=== | ||
*Allergic conditions: 0. | *Allergic conditions: 0.1mg/kg PO q6h | ||
**Max: 12.5 mg/dose during day, 25 mg/dose qhs | **Max: 12.5 mg/dose during day, 25 mg/dose qhs | ||
**May give additional dose of up to 0.5 mg/kg PO qhs | **May give additional dose of up to 0.5 mg/kg PO qhs | ||
| Line 28: | Line 28: | ||
**Avoid other resp. depressants | **Avoid other resp. depressants | ||
*Nausea/vomiting: 0.25- | *Nausea/vomiting: 0.25-1mg/kg PO/IM/IV q4-6h prn; | ||
**Max: 25 mg/dose | **Max: 25 mg/dose | ||
Revision as of 17:18, 20 July 2016
Administration
- Type: Antiemetic; Phenothiazine Derivative; Sedative
- Dosage Forms: 12.5,25,50; 6.25/5 mL sol; IM; IV
- Routes of Administration: Oral
- Common Trade Names: Phenadoz; Phenergan; Promethegan
Adult Dosing
- Allergic conditions: 6.25-12.5 mg PO tid
- May give additional dose of 12.5-25 mg PO qhs
- Nausea/vomiting: 12.5-25 mg PO/IM/IV q4-6h
- Max: 50mg/dose PO/IM; 25 mg/dose IV
- IM preferred over IV
- Motion sickness: 25 mg PO bid
- Start: 0.5-1h prior to travel
- Sedation: 25-50mg PO/IM/IV x1
- Max: 50mg/dose PO/IM; 25 mg/dose IV
- IM preferred over IV
Pediatric Dosing
Only Approved for >2 years
- Allergic conditions: 0.1mg/kg PO q6h
- Max: 12.5 mg/dose during day, 25 mg/dose qhs
- May give additional dose of up to 0.5 mg/kg PO qhs
- Use lowest effective dose
- Avoid other resp. depressants
- Nausea/vomiting: 0.25-1mg/kg PO/IM/IV q4-6h prn;
- Max: 25 mg/dose
- Motion sickness: 0.5 mg/kg PO q12h prn; Start: 0.5-1h before travel
- Max: 25 mg/dose; Info: use lowest effective dose
- Avoid other resp. depressants
- Sedation: 12.5-25 mg PO/IM/IV x1
- Max: 25 mg/dose
- IM preferred over IV
- Use lowest effective dose
- Avoid other resp. depressants
Special Populations
- Pregnancy Risk Factor: C
Renal Dosing
- No adjustment
Hepatic Dosing
- Caution advised with hepatic impairment
Contraindications
- Hypersensitivity to drug/component
- Patients <2 yo
- Comatose patients
- Respiratory depression
- SC injection
- intra- or periarterial administration
Adverse Reactions
Serious
- extravasation/tissue damage (IV use > IM use)
- apnea
- respiratory depression
- respiratory depression, fatal (infants)
- seizures
- leukopenia
- thrombocytopenia
- agranulocytosis
Common
- drowsiness
- sedation
- blurred vision
- dizziness
- confusion
- disorientation
Pharmacology
- Half-life: 7-14 hrs
- Metabolism: urine, feces
- Excretion: CYP450
Mechanism of Action
- nonselective antagonist of central and peripheral H1 receptors; anticholinergic
See Also
References
<UpToDate, Micromedex>
